Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Oral and Maxillofacial Pathology · Oral Leukoplakia

Does Dysplasia Grade Affect Oral Leukoplakia Cancer Risk?

At a Glance

In oral leukoplakia, higher-grade dysplasia generally means a higher chance of cancerous change, but it is not a guarantee. Biopsy results guide surveillance or removal, while lesion features, tobacco and alcohol exposure, and lifelong follow-up also affect risk.

Your biopsy report is one of the most important pieces of information your care team will use to manage your oral leukoplakia. The presence and severity of epithelial dysplasia—which measures how abnormal your cells look under a microscope—is a strong indicator of whether your leukoplakia might turn into oral cancer [1][2]. Generally, the more severe the dysplasia, the higher the risk of malignant transformation [3][4].

Hearing the words “dysplasia” or “carcinoma in situ” can be frightening. It is completely normal to feel anxious about these results. Remember that dysplasia is a risk marker, not a guarantee that you will develop cancer. The grade is a tool to guide treatment, not a crystal ball—even lesions with no dysplasia have a small risk of transforming, and some severe lesions never do [1][5]. Your personal risk depends on many factors, and population statistics cannot calculate your individual destiny. If your doctor discusses tobacco cessation or limiting alcohol, they are offering you concrete tools to reduce your future risk, not assigning blame for your diagnosis [2].

What the Grades Mean (and What They Don’t)

Pathologists evaluate your biopsy by looking at how abnormal the cells appear and how far these changes extend upward through the layers of the oral mucosa (the lining of your mouth). Crucially, in all grades of dysplasia, the abnormal cells have not crossed the boundary (the basement membrane) into the deeper tissues. If they cross that boundary, it is no longer dysplasia—it is invasive cancer.

Study estimates vary widely depending on the specific patient population, how long they were followed, and how they were treated. However, research generally shows this pattern of risk:

  • No Dysplasia (Hyperkeratosis or Hyperplasia): The cells are growing more than usual, but they do not look inherently abnormal [5]. Studies looking at 5-year outcomes in large groups found a roughly 2% risk of transformation [1].
  • Mild and Moderate Dysplasia: The abnormal cells are confined to the lower or middle portions of the lining [6]. In a large 5-year study, groups with mild or moderate dysplasia both showed an approximate 8% to 12% risk of transformation [1]. The risks for mild and moderate often overlap in real-world practice [1].
  • Severe Dysplasia and Carcinoma in Situ (CIS): The abnormal cells extend through most or all layers of the lining, but have not invaded deeper tissues [6][7]. Carcinoma in situ is a “Stage 0” pre-invasive diagnosis. While not yet cancer, it carries the highest risk of transformation, with some pooled studies estimating up to a 30% to 40% risk over time if grouped with severe dysplasia [8].

Decoding Your Pathology Report

Report Term What It Means What Your Doctor Might Discuss
No Dysplasia (Hyperkeratosis) Thicker lining, but cells look generally normal. Not cancer. Active surveillance and modifying lifestyle risks.
Mild Dysplasia (Low-Grade) Abnormal cells confined to the lower layers of the lining. Usually active surveillance; sometimes removal if the lesion is large or changing.
Moderate Dysplasia (Low or High-Grade) Abnormal cells in the lower and middle layers. An individualized discussion weighing surgical removal versus close surveillance.
Severe Dysplasia / Carcinoma In Situ (High-Grade) Abnormal cells throughout most/all layers, but have not invaded deeper tissue. Prompt specialist planning for surgical removal, ensuring the tissue can be examined in a lab.

Two Grading Systems

You might notice different terms used by different pathologists. There are two main ways to grade oral dysplasia [9]:

  1. The Traditional Three-Tier System (WHO): This categorizes the lesion as mild, moderate, or severe dysplasia (with CIS typically grouped with severe) [6].
  2. The Binary System: This newer method simplifies the grades into two categories: low-grade (mild and some moderate) and high-grade (severe, CIS, and the rest of the moderate cases) [8][9].

Why two systems? Diagnosing dysplasia is somewhat subjective. Two highly trained pathologists looking at the exact same slide might sometimes disagree on whether it is “mild” or “moderate” [7]. The binary system was created to make grading simpler and more consistent across different labs [10][11].

Limitations: Sampling Error and Other Risk Factors

While the grade is crucial, it has limitations you should understand:

  • Sampling Error: An incisional biopsy only tests a tiny piece of the patch. In up to 31% of cases, the full lesion may harbor more severe dysplasia than what was caught in the initial small sample [12]. This is why your doctor will continually evaluate the visual appearance of your leukoplakia, not just the biopsy grade.
  • Grade is Only One Factor: Your individual risk is heavily influenced by other factors. Higher risk is associated with lesions on the sides of the tongue or floor of the mouth, lesions that are red-and-white (nonhomogeneous) rather than purely white, larger lesions, and a condition called proliferative verrucous leukoplakia [13][14].

How Grade Influences Your Care Options

There is no universal treatment protocol for every grade, because your specialist will weigh the pathology report against the lesion’s size, its location, and your overall health. However, the general approach involves:

  • Active Surveillance: For lesions with no dysplasia or mild dysplasia, specialists often recommend close monitoring rather than immediate surgery [14].
  • Surgical Removal vs. Ablation: For severe dysplasia and CIS, specialists generally recommend removing the lesion [14][15]. Surgical excision involves cutting out the patch so the entire piece can be examined in a lab to ensure no invasive cancer was missed. Laser ablation vaporizes the tissue; while it removes the patch, it destroys the tissue, meaning the pathologist cannot check the margins or look for hidden cancer. Because of this, excision is often preferred when invasion is suspected [16]. The approach to moderate dysplasia varies widely and requires a highly individualized discussion.

What Happens Next?

  • If Active Surveillance is chosen: You will likely have clinical exams every few months. Your doctor will visually check the lesion and may take another biopsy if the patch changes color, size, or texture.
  • If Surgery is chosen: The area will be numbed and the patch removed. While the mouth heals relatively quickly, there may be temporary discomfort with eating or speaking. Crucially, if the lesion is excised, the tissue is sent back to the lab to confirm the final grade and ensure no invasive cancer was hiding in the margins.

The Need for Lifelong Follow-Up

Treatment does not permanently eliminate your risk. Even after surgical removal, roughly 22% of leukoplakia patches recur [13]. This can happen because the surrounding tissue in your mouth was exposed to the same risk factors (like tobacco)—a concept known as “field cancerization” [17]. Whether you had surgery or are on active surveillance, you will need lifelong follow-up [18].

When to Call Your Doctor Sooner:
Do not wait for your next scheduled appointment if you notice any of these “red flag” changes in your mouth:

  • Rapid growth or spreading of the white patch
  • New red, bleeding, or ulcerated areas that do not heal
  • A firm lump, hardening of the tissue, or increasing pain
  • Numbness, or difficulty moving your tongue, chewing, or swallowing
  • A new lump in your neck

Common questions in this guide

What does dysplasia mean on an oral leukoplakia biopsy?
Dysplasia means that cells in the mouth lining look abnormal under a microscope. It is a warning sign that the patch has a higher chance of changing into cancer, but it is not cancer by itself. In dysplasia, the abnormal cells have not grown through the tissue boundary into deeper areas.
Does severe dysplasia mean I already have oral cancer?
No. Severe dysplasia and carcinoma in situ are pre-invasive changes: abnormal cells may involve most or all of the mouth lining, but they have not invaded deeper tissue. They carry the highest risk of later cancerous change, so prompt specialist planning is usually recommended.
What is the cancer risk for each oral leukoplakia dysplasia grade?
In one large five-year study, patches with no dysplasia had about a 2% risk of changing into cancer, while mild and moderate dysplasia each had roughly an 8% to 12% risk. Pooled studies estimate up to about 30% to 40% over time for severe dysplasia or carcinoma in situ grouped together. Estimates vary by the people studied, follow-up time, and treatment, so they cannot predict one person's outcome.
Can a biopsy miss more severe dysplasia in an oral leukoplakia patch?
Yes. An incisional biopsy examines only a small piece of the patch, and in up to about 31% of cases the rest of the lesion may contain more severe changes. Your clinician therefore considers the patch's full appearance and may recommend another biopsy or removal if it changes.
How does dysplasia grade affect oral leukoplakia treatment?
No single grade determines treatment because lesion size, location, appearance, biopsy limits, and overall health also matter. No dysplasia or mild dysplasia is often monitored, moderate dysplasia is handled case by case, and severe dysplasia or carcinoma in situ usually leads to discussion of surgical removal. Excision preserves tissue for laboratory examination, whereas laser ablation destroys the tissue.
Do I need follow-up after oral leukoplakia is removed?
Yes. Leukoplakia can recur even after surgery, and the surrounding mouth tissue may remain at risk, so lifelong follow-up is recommended. Clinical exams can identify changes early, and tobacco cessation and limiting alcohol can help reduce future risk.

Get notified when new evidence is published on oral mucosa leukoplakia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Oral Leukoplakia and Risk of Progression to Oral Cancer: A Population-Based Cohort Study.

    Chaturvedi AK, Udaltsova N, Engels EA, et al.

    Journal of the National Cancer Institute 2020; (112(10)):1047-1054 doi:10.1093/jnci/djz238.

    PMID: 31860085
  2. 2

    Integrated Clinical, Histopathological, and Inflammatory Parameters for Predicting Malignant Transformation in High-Risk Oral Potentially Malignant Disorders: A Prospective Study.

    Chavda R, Rane SU, Mittal N, et al.

    Head and neck pathology 2026; (20(1)).

    PMID: 41843309
  3. 3

    Malignant transformation rate of oral leukoplakia in the past 20 years: A systematic review and meta-analysis.

    Guan JY, Luo YH, Lin YY, et al.

    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2023; (52(8)):691-700 doi:10.1111/jop.13440.

    PMID: 37224426
  4. 4

    Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta-analysis of malignant transformation rate by subtype.

    Iocca O, Sollecito TP, Alawi F, et al.

    Head & neck 2020; (42(3)):539-555 doi:10.1002/hed.26006.

    PMID: 31803979
  5. 5

    Malignant Transformation Rate of Non-reactive Oral Hyperkeratoses Suggests an Early Dysplastic Phenotype.

    Stojanov IJ, Woo SB

    Head and neck pathology 2022; (16(2)):366-374 doi:10.1007/s12105-021-01363-z.

    PMID: 34255278
  6. 6

    Oral Pre-malignancy: An Update on Novel Therapeutic Approaches.

    Naara S, Andrews C, Sikora A, et al.

    Current oncology reports 2024; (26(9)):1047-1056 doi:10.1007/s11912-024-01562-1.

    PMID: 38865005
  7. 7

    Oral epithelial dysplasia, atypical verrucous lesions and oral potentially malignant disorders: focus on histopathology.

    Müller S

    Oral surgery, oral medicine, oral pathology and oral radiology 2018; (125(6)):591-602 doi:10.1016/j.oooo.2018.02.012.

    PMID: 29606637
  8. 8

    Binary and WHO dysplasia grading systems for the prediction of malignant transformation of oral leukoplakia and erythroplakia: a systematic review and meta-analysis.

    de Freitas Silva BS, Batista DCR, de Souza Roriz CF, et al.

    Clinical oral investigations 2021; (25(7)):4329-4340 doi:10.1007/s00784-021-04008-1.

    PMID: 34050426
  9. 9

    Grading systems of oral cavity pre-malignancy: a systematic review and meta-analysis.

    Yan F, Reddy PD, Nguyen SA, et al.

    European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2020; (277(11)):2967-2976 doi:10.1007/s00405-020-06036-1.

    PMID: 32447493
  10. 10

    Oral epithelial dysplasia grading: Comparing the binary system to the traditional 3-tier system, an actuarial study with malignant transformation as outcome.

    Sperandio M, Warnakulasuriya S, Soares AB, et al.

    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2023; (52(5)):418-425 doi:10.1111/jop.13365.

    PMID: 36177736
  11. 11

    The clinical utility of contemporary oral epithelial dysplasia grading systems.

    Sathasivam HP, Sloan P, Thomson PJ, Robinson M

    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2022; (51(2)):180-187 doi:10.1111/jop.13262.

    PMID: 34797585
  12. 12

    Diagnostic discrepancies in the surgical management of oral epithelial dysplasia - an analysis of concordance between incisional biopsy and definitive resection specimens.

    Maloney B, Jung MS, Byrne J, et al.

    Oral surgery, oral medicine, oral pathology and oral radiology 2026; (142(3)):362-374 doi:10.1016/j.oooo.2026.03.001.

    PMID: 42020233
  13. 13

    Recurrence in Oral Leukoplakia: A Systematic Review and Meta-analysis.

    Bhattarai BP, Singh AK, Singh RP, et al.

    Journal of dental research 2024; (103(11)):1066-1075 doi:10.1177/00220345241266519.

    PMID: 39290142
  14. 14

    Malignant transformation of oral leukoplakia: a follow-up study.

    Jayasooriya PR, Dayaratne K, Dissanayake UB, Warnakulasuriya S

    Clinical oral investigations 2020; (24(12)):4563-4569 doi:10.1007/s00784-020-03322-4.

    PMID: 32436158
  15. 15

    Randomized Controlled Trials for Oral Leukoplakia.

    Lodolo M, Valor J, Villa A

    Oral diseases 2025; doi:10.1111/odi.15399.

    PMID: 40457716
  16. 16

    Surgical protocols for oral leukoplakia and precancerous lesions across three different anatomic sites.

    Pedroso CM, do Santos ES, Alves FA, et al.

    Oral diseases 2025; (31(1)):89-98 doi:10.1111/odi.15098.

    PMID: 39155483
  17. 17

    New insights into the genetic progression of cancer through longitudinal analysis of oral lesions.

    Wils LJ, Poell JB, Brink A, et al.

    The Journal of pathology 2025; (267(2)):155-167 doi:10.1002/path.6449.

    PMID: 40728388
  18. 18

    Proliferative verrucous leukoplakia: a case report of multiple metachronous oral verrucous carcinoma.

    Lombardi N, Varoni EM, Franchini R, Lodi G

    BMJ case reports 2023; (16(11)) doi:10.1136/bcr-2023-256383.

    PMID: 37967933

This page is for informational purposes only and does not constitute medical advice. Your oral and maxillofacial specialist or pathologist should interpret your biopsy and recommend follow-up for your specific lesion.